TAR Required for Hydroxychloroquine and Chloroquine for COVID-19 Treatment

June 19, 2020

On June 15, 2020, the U.S. Food and Drug Administration (FDA) revoked its decision from March 28th allowing use of Hydroxychloroquine and Chloroquine to treat people hospitalized with coronavirus disease 2019 (COVID-19) under an emergency use authorization (EUA). In light of the guidance issued by the FDA, effective immediately, beneficiaries requiring COVID-19 treatment with Hydroxychloroquine and Chloroquine should obtain the medication through either an established clinical trial, or through a Treatment Authorization Request (TAR) or Service Authorization Request (SAR) approval for off-label use of Hydroxychloroquine and Chloroquine outside of clinical trials. Please see the full article on the DHCS Medi-Cal COVID-19 webpage at: Fee-for-Service Pharmacy: Flexibilities for Off-Label/Investigational Drugs in COVID-19-Related Treatment (Updated on June 18, 2020).